Clinical progress continues in cell therapy with promising data from EsoBiotec’s in vivo CAR-T therapy showing responses in multiple myeloma patients, and Australian researchers developing CRISPR-edited CAR T cells that activate anti-cancer proteins at tumor sites. ProKidney’s rilparencel cell therapy for chronic kidney disease showed significant efficacy in one phase 2 cohort supporting ongoing phase 3 studies. Conversely, Taiho Pharmaceutical's Duchenne muscular dystrophy candidate failed to meet primary endpoints in phase 3 trials. These developments highlight a dynamic landscape for gene and cell therapies across multiple indications.